Endocrine Abstracts

Introduction: Obesity is a global public health challenge. Semaglutide, a weekly GLP-1 agonist, was recently approved in Europe for weight loss. There is paucity of real-life data about the effectiveness and safety of semaglutide for weight management.Methods: Real-world data of semaglutide use in a weight management clinic in Athens, Greece, for individuals with BMI (body mass index) > 30 kg/square meter without diabetes, including all patients with...

Background: Obesity, a chronic relapsing disease, has become a global public health challenge. Semaglutide, a weekly glucagon-like peptide-1 (GLP-1) agonist which has shown unprecedentedly high efficacy in randomised controlled trials, was recently approved in Europe for weight loss. There is paucity of real-life data about its effectiveness and safety for weight management.Methods: Our aim was to evaluate the changes in weight and metab...

Introduction: Moderate to severe thyroid eye disease (TED) has a significant impact on quality of life. In some cases, TED is resistant to systemic glucocorticoids, the mainstay of treatment since the 1950s, requiring alternative therapies. We describe here a patient with active severe TED who is refractory to various treatments.Case presentation: A 48-year-old non-smoker male, with a long history of psoriasis, vitiligo and atrophic gastritis, presented ...

Introduction: Obesity, a chronic disease, is recognised as a major public health problem. In 2023, the National Institute for Health and Care Excellence (NICE) recommended semaglutide, a weekly glucagon-like peptide-1 (GLP-1) agonist, as a pharmacological option for weight management. This case series aims to evaluate the real-world effectiveness and safety profile of semaglutide therapy for weight loss.Methods: Retrospe...

Introduction: The prevalence of obesity, a chronic disease with significant morbidity, has rapidly increased in recent decades. Semaglutide, an injectable glucagon-like peptide-1 agonist, has gained global popularity after its approval for weight management in 2021. All studies have reported marked variability in semaglutide response, with a small proportion of patients (10-16%) showing inadequate response. Data about the predictors of poor response to semaglutide for weight l...

Introduction: Hyponatraemia is the most common electrolyte abnormality encountered in hospitalised patients.Methods: This retrospective study included all inpatients with serum sodium ≤128 mmol/l at any point during their hospital stay between 1st March 2013 and 31st May 2013. Full review of medical case notes and laboratory results was undertaken in order to determine the comorbidities, drug history and aetiology of inpatients with hyponatraemia.<...

Introduction: Hyponatraemia is associated with increased inpatient mortality, but there is debate about whether hyponatraemia per se contributes to mortality or is merely an epiphenomenon of severe illness.Methods: This retrospective review of medical records included all inpatients with serum sodium (sNa)≤128 mmol/l who died at a teaching hospital over a 3-month period. The aim of this study was to examine the clinical course and the pote...

A 56-year-old woman, recently commenced on immunotherapy as second-line treatment for advanced non-small cell lung cancer, presented at the hospital critically unwell with severe diabetic ketoacidosis (DKA) (glucose 47 mmol/l, blood ketones 7.5 mmol/l, pH 6.95, bicarbonate 6.6 mmol/l). One week prior to presentation, she was clinically well with random glucose of 6.1 mmol/l. Following admission to Intensive Care Unit, she responded well to standard treatment for DKA and discha...

Aims: Low vitamin D levels may contribute to the pathogenesis of bone disease in thalassaemia major patients. Our haematology department serves one of the UK’s largest populations of thalassaemia patients. We evaluated our thalassaemia major patients’ vitamin D levels and other serum bone markers.Methods: Blood specimens were collected from all thalassaemia major patients under active follow-up in March and April 2010 and serum 25-OH-vitamin D,...

Aims: Endocrine deficiencies are common complications of thalassaemia major. Our haematology department serves one of the UK’s largest populations of thalassaemia patients. We assessed our thalassaemia major patients’ endocrine status and factors associated with endocrinopathies.Methods: Retrospective analysis of our thalassaemia major patients on active follow-up in April 2010. Parameters such as age, gender, hepatitis C infection, compliance ...